<p>MRM chromatograms of a plasma sample from a patient which have been treated with dabigatran are depicted on the left (A, B, E, F), as well as MRM chromatograms a plasma sample from a patient which have been treated with rivaroxaban are depicted on the right (I, J, M, N). MRM chromatograms of the internal standard [<sup>13</sup>C<sub>6</sub>]-dabigatran (C, D, K, L) concerning dabigatran, as well as the internal standard [<sup>13</sup>C<sub>6</sub>]-rivaroxaban (G, H, O, P) concerning rivaroxaban are also shown. The first mass transition which was used for quantification of the drug, as well as the second mass transition which was used for verification is plotted. Data were normalized to largest peak in the plots. An estimated peak height...
<p>The figure shows Ifosfamide and cyclophosphamide on 24-h samples. Selectivity to other drugs admi...
<p>(MTX-total): Chromatogram after conversion of total MTXPGs to MTXPG<sub>1</sub>; total concentrat...
\u3cp\u3eBackground: Three novel direct oral anticoagulants (DOACs) have recently been registered by...
<p>MRM chromatograms of a plasma sample without any DOACs are depicted on the left (A, B, E, F), as ...
The fast, precise, and accurate measurement of the new generation of oral anticoagulants such as dab...
<p>MRM chromatograms of (A) NAGLy in a standard solution (136 pg on column) and (B) a representative...
\(\textbf {Introduction:}\) The fast, precise, and accurate measurement of the new generation of or...
<p>(A): SRM chromatograms of a human blank plasma sample; (B): SRM chromatograms of a human blank pl...
AIM: Novel oral anticoagulants are characterized by a wide therapeutic window, yet the determinatio...
<p>Ion suppression profile for dabigatran is depicted on the left and for rivaroxaban is depicted on...
<p>(A) Extracted blank (y axis:0–520 CPS), (B) extracted IS (0.14 μM; y axis:0–2.3e<sup>6</sup> CPS)...
<p>Representative MRM chromatograms of a blank DBS sample (A), DBS spiked with MTXPGs (final total c...
<p>(A) Measurement of rivaroxaban in rivaroxaban and dabigatran spiked plasma. Concentrations were q...
<p>Representative MRM-chromatogram of loperamide (quantifier ion in blue, qualifier ion red) and of ...
<p>Representative MRM chromatograms of (A) ceftazidime; (B) minocycline; (C) cefotaxime; (D) netilmi...
<p>The figure shows Ifosfamide and cyclophosphamide on 24-h samples. Selectivity to other drugs admi...
<p>(MTX-total): Chromatogram after conversion of total MTXPGs to MTXPG<sub>1</sub>; total concentrat...
\u3cp\u3eBackground: Three novel direct oral anticoagulants (DOACs) have recently been registered by...
<p>MRM chromatograms of a plasma sample without any DOACs are depicted on the left (A, B, E, F), as ...
The fast, precise, and accurate measurement of the new generation of oral anticoagulants such as dab...
<p>MRM chromatograms of (A) NAGLy in a standard solution (136 pg on column) and (B) a representative...
\(\textbf {Introduction:}\) The fast, precise, and accurate measurement of the new generation of or...
<p>(A): SRM chromatograms of a human blank plasma sample; (B): SRM chromatograms of a human blank pl...
AIM: Novel oral anticoagulants are characterized by a wide therapeutic window, yet the determinatio...
<p>Ion suppression profile for dabigatran is depicted on the left and for rivaroxaban is depicted on...
<p>(A) Extracted blank (y axis:0–520 CPS), (B) extracted IS (0.14 μM; y axis:0–2.3e<sup>6</sup> CPS)...
<p>Representative MRM chromatograms of a blank DBS sample (A), DBS spiked with MTXPGs (final total c...
<p>(A) Measurement of rivaroxaban in rivaroxaban and dabigatran spiked plasma. Concentrations were q...
<p>Representative MRM-chromatogram of loperamide (quantifier ion in blue, qualifier ion red) and of ...
<p>Representative MRM chromatograms of (A) ceftazidime; (B) minocycline; (C) cefotaxime; (D) netilmi...
<p>The figure shows Ifosfamide and cyclophosphamide on 24-h samples. Selectivity to other drugs admi...
<p>(MTX-total): Chromatogram after conversion of total MTXPGs to MTXPG<sub>1</sub>; total concentrat...
\u3cp\u3eBackground: Three novel direct oral anticoagulants (DOACs) have recently been registered by...